Medical Supply International USA, Inc.

Medical Supply International USA, Inc., together with its subsidiaries, provides rehabilitation services and specialized hospital services in the healthcare industry in the People's Republic of China. It operates rehabilitative center, and maternity and specialized service hospital. The rehabilitative center serves patients who have survived from a serious injury or illness or an addiction and are seeking therapeutic or medical treatment. The company also operates outpatient clinic and offers other services, including private outpatients and health check-up services, and obstetrics and gynecology services. It offers 4-D ultrasound system applications for scanning for medical purposes, IPL system applications for treatment various kinds of skin disorder, and cosmetic surgery. The company was formerly known as Master Spirit International USA Inc. and changed its name to Medical Supply International USA, Inc. in October 2018. Medical Supply International USA, Inc. was founded in 2001 and is headquartered in Wan Chai, Hong Kong.

Medical Supply International USA, Inc. trades as MSIU on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.82M of revenue and $394,840 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Medical Supply International USA, Inc. can be compared against peers such as Bespoke Extracts, Inc., Strainsforpains, Inc., Khiron Life Sciences Corp., Kelyniam Global, Inc., CordovaCann Corp., Pressure BioSciences, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $20,405, beta of -221.38, and return on equity of +204.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

MSIU currently shows total debt of $227,002 and beta of -221.38. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.medicalsupplyinternational.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.